drugset / Trial / NCT00199056

German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99)

NCT00199056 ↗

Phase 4 Completed 225 enrolled Goethe University
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The study evaluates the efficacy and tolerability of an intensified induction and consolidation therapy. Thereafter patients receive individualised treatment stratified according to relapse risk with stem cell transplantation for patients with high and very high risk of relapse. Patients with standard risk receive further consolidation and reinduction chemotherapy. In parallel minimal residual disease (MRD) is evaluated. A MRD based risk stratification and treatment decision is developed.

Timeline

Start
1999-10
Primary completion
2003-11
Completion
2005-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified — —
Subject Cytarabine Small molecule — —
Subject Daunorubicin Small molecule — —
Subject Dexamethasone Small molecule — —
Subject Doxorubicin Other / unclassified — —
Subject Etoposide Small molecule — —
Subject Fludarabine Small molecule — —
Subject Idarubicin Small molecule — —
Subject Ifosfamide Small molecule — —
Subject MERCAPTOPURINE ANHYDROUS Small molecule — —
Subject Methotrexate Small molecule — —
Subject Prednisolone Other / unclassified — —
Subject Teniposide Small molecule — —
Subject Thioguanine Small molecule — —
Subject Vincristine Small molecule — —
Subject Vindesine Small molecule — —
Subject asparaginase Protein / enzyme biologic — —